Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

933.39 +8.96 (+0.97%)
Streaming Delayed Price Updated: 10:02 AM EDT, Sep 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 357,423
Open 931.79
Bid (Size) 932.31 (2)
Ask (Size) 933.39 (4)
Prev. Close 924.43
Today's Range 931.50 - 939.30
52wk Range 516.57 - 972.53
Shares Outstanding N/A
Dividend Yield 0.48%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly Touts Results Of EU-Approved Dermatitis Treatment, Shows Sustained Disease Control For Up To Three Years
Eli Lilly presents promising long-term data showing Ebglyss' efficacy in treating moderate-to-severe atopic dermatitis, with over 80% of patients maintaining clear skin for up to three years. FDA and... 
Via Benzinga
Exposures Product Safety
Why This Stock Could Be the Nvidia of Healthcare
The opportunities for artificial intelligence (AI) to have an impact in the healthcare space are enormous. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+57.61%
+57.61%
1 Month
-1.80%
-1.80%
3 Month
+3.18%
+3.18%
6 Month
+20.45%
+20.45%
1 Year
+69.00%
+69.00%

More News

Read More
$1000 Invested In Eli Lilly 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Via MarketBeat
Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market
Via Benzinga
Spotlight on Eli Lilly: Analyzing the Surge in Options Activity
Via Benzinga
In-Depth Analysis: Eli Lilly Versus Competitors In Pharmaceuticals Industry
Via Benzinga
Looking Into Eli Lilly's Recent Short Interest
Via Benzinga
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
Via FinancialNewsMedia
Exposures Product Safety
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
From FN Media Group LLC
Via GlobeNewswire
Unpacking the Latest Options Trading Trends in Eli Lilly
Via Benzinga
Investing in This Healthcare Stock Could Be Like Catching Nvidia at the Dawn of the AI Boom
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Prediction: This Is What Eli Lilly Stock Will Do Next (Hint: It's Not a Stock Split)
Via The Motley Fool
Netflix, Eli Lilly Lead 5 Fast Growers Near Buy Points
Via Investor's Business Daily
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
Via The Motley Fool
US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Eli Lilly Fights $183M Medicaid Fraud Judgment, Cites Reasonable Interpretation Of Medicaid Rules
Via Benzinga
Topics Fraud
Exposures Legal
Why Tandem Diabetes Care Stock Thrashed the Market Today
Via The Motley Fool
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
Via Investor's Business Daily
1 Unstoppable Stock That Could Join the $1 Trillion Club in 2025
Via The Motley Fool
Prediction: This Will be Eli Lilly's Next Big Move.
Via The Motley Fool
Why ResMed Stock Tumbled by 5% Today
Via The Motley Fool
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Via The Motley Fool
ADX: A High-Yielding, Diversified CEF Worth Looking Into
Via Talk Markets
Prediction: This Will Be the First Healthcare Stock to Join the Trillion-Dollar Club
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.